HK1136820A1 - Substituted arylimidazolone and triazolone as inhibitors of vasopressin receptors - Google Patents

Substituted arylimidazolone and triazolone as inhibitors of vasopressin receptors

Info

Publication number: HK1136820A1
Authority: HK; Hong Kong
Prior art keywords: arylimidazolone; triazolone; inhibitors; substituted; vasopressin receptors
Prior art date: 2006-05-23

Application number

HK10100511.8A

Other languages

English (en)

Chinese (zh)

Inventor

Heinrich Meier

Eckhard Bender

Ulf Brggemeier

Ingo Flamme

Dagmar Karthaus

Peter Kolkhof

Daniel Meibom

Dirk Schneider

Verena Voehringer

Chantal Frstner

Jrg Keldenich

Dieter Lang

Elisabeth Pook

Carsten Schmeck

Original Assignee

Bayer Ip Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-05-23

Filing date

2010-01-18

Publication date

2010-07-09

2010-01-18 Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh

2010-07-09 Publication of HK1136820A1 publication Critical patent/HK1136820A1/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/12—Oxygen or sulfur atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/70—One oxygen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Cardiology (AREA)
Hematology (AREA)
Diabetes (AREA)
Heart & Thoracic Surgery (AREA)
Obesity (AREA)
Hospice & Palliative Care (AREA)
Gastroenterology & Hepatology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)

HK10100511.8A 2006-05-23 2010-01-18 Substituted arylimidazolone and triazolone as inhibitors of vasopressin receptors HK1136820A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE102006024024A DE102006024024A1 (de)	2006-05-23	2006-05-23	Substituierte Arylimidazolone und -triazolone sowie ihre Verwendung
PCT/EP2007/004615 WO2007134862A1 (de)	2006-05-23	2007-05-21	Substituierte arylimidaz0l0ne und -triaz0l0ne als inhibitoren der vasopressin-rezeptoren

Publications (1)

Publication Number	Publication Date
HK1136820A1 true HK1136820A1 (en)	2010-07-09

Family

ID=38353593

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HK10100511.8A HK1136820A1 (en)	2006-05-23	2010-01-18	Substituted arylimidazolone and triazolone as inhibitors of vasopressin receptors

Country Status (30)

Country	Link
US (2)	US8084481B2 (xx)
EP (1)	EP2027096B8 (xx)
JP (1)	JP5247684B2 (xx)
KR (1)	KR101426574B1 (xx)
CN (1)	CN101495458B (xx)
AR (1)	AR061114A1 (xx)
AU (1)	AU2007253572B9 (xx)
BR (1)	BRPI0711975A2 (xx)
CA (1)	CA2652834C (xx)
DE (1)	DE102006024024A1 (xx)
DK (1)	DK2027096T3 (xx)
DO (1)	DOP2007000102A (xx)
EC (1)	ECSP088904A (xx)
ES (1)	ES2385606T3 (xx)
GT (1)	GT200800250A (xx)
HK (1)	HK1136820A1 (xx)
HN (1)	HN2008001720A (xx)
IL (1)	IL195142A (xx)
MA (1)	MA30500B1 (xx)
MX (1)	MX2008014797A (xx)
PE (1)	PE20080706A1 (xx)
PL (1)	PL2027096T3 (xx)
PT (1)	PT2027096E (xx)
RU (1)	RU2460724C2 (xx)
SV (1)	SV2009003098A (xx)
TN (1)	TNSN08443A1 (xx)
TW (1)	TW200817336A (xx)
UY (1)	UY30364A1 (xx)
WO (1)	WO2007134862A1 (xx)
ZA (1)	ZA200809860B (xx)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE102006024024A1 (de) *	2006-05-23	2007-11-29	Bayer Healthcare Aktiengesellschaft	Substituierte Arylimidazolone und -triazolone sowie ihre Verwendung
MX2011003780A (es) *	2008-10-10	2011-05-03	Janssen Pharmaceutica Nv	Terapia de combinacion que comprenden bloqueadores del receptor de la angiotensina y antagonistas del receptor de la vasopresina.
DE102008060967A1 (de) *	2008-12-06	2010-06-10	Bayer Schering Pharma Aktiengesellschaft	Substituierte Phenylsulfonyltriazolone und ihre Verwendung
DE102010001064A1 (de)	2009-03-18	2010-09-23	Bayer Schering Pharma Aktiengesellschaft	Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung
DE102009013642A1 (de) *	2009-03-18	2010-09-23	Bayer Schering Pharma Aktiengesellschaft	Substituierte Phenylalaninderivate und deren Verwendung
DE102009028929A1 (de) *	2009-08-27	2011-07-07	Bayer Schering Pharma Aktiengesellschaft, 13353	Heterocyclisch-substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung
WO2011104322A1 (de)	2010-02-27	2011-09-01	Bayer Pharma Aktiengesellschaft	Bis-arylverknüpfte aryltriazolone und ihre verwendung
WO2011150286A2 (en)	2010-05-26	2011-12-01	Satiogen Pharmaceuticals,Inc.	Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
DE102010040187A1 (de) *	2010-09-02	2012-03-08	Bayer Schering Pharma Aktiengesellschaft	Substituierte N-Phenethyl-triazolonacetamide und ihre Verwendung
DE102010040924A1 (de) *	2010-09-16	2012-03-22	Bayer Schering Pharma Aktiengesellschaft	Substituierte Phenylacet- und Phenylpropanamide und ihre Verwendung
ME02169B (me)	2010-10-01	2015-10-20	Taisho Pharmaceutical Co Ltd	Derivat 1,2,4-triazolona
CN102260154A (zh) *	2011-06-10	2011-11-30	南通职业大学	一种医药中间体α-溴代对氯苯丙酮的制备方法
CN102875499B (zh) *	2011-07-12	2015-08-19	天津药明康德新药开发有限公司	3-氨甲基氧杂环丁烷及其有机酸盐的制备方法
RS56823B1 (sr) *	2011-07-29	2018-04-30	Karyopharm Therapeutics Inc	Modulatori nukleusnog transporta koji sadrže hidrazid i njihove upotrebe
CA2853227C (en)	2011-10-27	2019-05-14	Taisho Pharmaceutical Co., Ltd.	Azole derivative
EP3278796A1 (en)	2011-10-28	2018-02-07	Lumena Pharmaceuticals LLC	Bile acid recycling inhibitors for treatment of hypercholemia and cholestatic liver disease
BR112014010223B8 (pt)	2011-10-28	2021-02-23	Lumena Pharmaceuticals Llc	uso de uma composição compreendendo inibidores de reciclagem de ácido de bílis e forma de dosagem pediátrica
CN105228607A (zh)	2013-03-15	2016-01-06	鲁美纳医药公司	用于治疗原发性硬化性胆管炎和炎性肠病的胆汁酸再循环抑制剂
RU2015139732A (ru)	2013-03-15	2017-04-24	ЛУМЕНА ФАРМАСЬЮТИКАЛС ЭлЭлСи	Ингибиторы рециркуляции желчных кислот для лечения пищевода барретта и гастроэзофагеальной рефлюксной болезни
JP6387669B2 (ja) *	2013-04-26	2018-09-12	大正製薬株式会社	アゾール誘導体を含有する医薬
US10023567B2 (en) *	2014-07-18	2018-07-17	Ohio University	Imidazole and thiazole compositions for modifying biological signaling
SG11201703199UA (en)	2014-11-03	2017-05-30	Bayer Pharma AG	Hydroxyalkyl-substituted phenyltriazole derivatives and uses thereof
GB201504763D0 (en) *	2015-03-20	2015-05-06	Mironid Ltd	Compounds and uses
US10800746B2 (en) *	2016-05-03	2020-10-13	Bayer Pharma Aktiengesellschaft	Oxoalkyl-substituted phenyltriazole derivatives and uses thereof
US9988367B2 (en)	2016-05-03	2018-06-05	Bayer Pharma Aktiengesellschaft	Amide-substituted pyridinyltriazole derivatives and uses thereof
WO2017191117A1 (en)	2016-05-03	2017-11-09	Bayer Pharma Aktiengesellschaft	V1a receptor antagonists for use in the treatment of renal diseases
US20200337590A1 (en)	2018-01-16	2020-10-29	Bayer Aktiengesellschaft	Assistance in the treatment of cardiac insufficiency
AU2020223022A1 (en)	2019-02-12	2021-09-02	Mirum Pharmaceuticals, Inc.	Methods for increasing growth in pediatric subjects having cholestatic liver disease
WO2021127459A1 (en) *	2019-12-20	2021-06-24	Blackthorn Therapeutics, Inc.	Gpr139 receptor modulators
EP4405348A1 (en)	2021-09-20	2024-07-31	Basf Se	Heterocyclic compounds for the control of invertebrate pests

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3042466A1 (de)	1980-11-11	1982-06-16	A. Nattermann & Cie GmbH, 5000 Köln	N-substituierte (omega) -(2-oxo-4-imidazolin-l-yl)-alkansaeure-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate
EP0412594B1 (en)	1989-07-28	1996-01-03	Merck & Co. Inc.	Substituted triazolinones, triazolinethiones, and triazolinimines as angiotensin II antagonists
US5468448A (en) *	1989-12-28	1995-11-21	Ciba-Geigy Corporation	Peroxide disinfection method and devices therefor
DE4107857A1 (de)	1991-03-12	1992-09-17	Thomae Gmbh Dr K	Cyclische harnstoffderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
IT1251488B (it)	1991-09-17	1995-05-15	Mini Ricerca Scient Tecnolog	Ossa(tia)diazol- e triazol-oni(tioni) ad attivita' acaricida ed insetticida
RU2116304C1 (ru) *	1992-04-28	1998-07-27	Такеда Кемикал Индастриз, Лтд.	Производные азола, способ их получения, фармацевтическая композиция
SK94393A3 (en)	1992-09-11	1994-08-10	Thomae Gmbh Dr K	Cyclic derivatives of urea, process for their production and their pharmaceutical agents with the content of those
US6844005B2 (en) *	2002-02-25	2005-01-18	Trutek Corp	Electrostatically charged nasal application product with increased strength
FR2708608B1 (fr) *	1993-07-30	1995-10-27	Sanofi Sa	Dérivés de N-sulfonylbenzimidazolone, leur préparation, les compositions pharmaceutiques en contenant.
US5897858A (en) *	1994-02-03	1999-04-27	Schering-Plough Healthcare Products, Inc.	Nasal spray compositions exhibiting increased retention in the nasal cavity
TW467902B (en) *	1996-07-31	2001-12-11	Bristol Myers Squibb Co	Diphenyl heterocycles as potassium channel modulators
DE19741235A1 (de) *	1997-09-18	1999-03-25	Hoechst Marion Roussel De Gmbh	Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DK1040111T3 (da)	1997-12-17	2005-10-10	Merck & Co Inc	Integrinreceptorantagonister
DE19816882A1 (de) *	1998-04-17	1999-10-21	Boehringer Ingelheim Pharma	Triazolone mit neuroprotektiver Wirkung
DE19914140A1 (de) *	1999-03-27	2000-09-28	Bayer Ag	Substituierte Benzoylpyrazole
DE19920791A1 (de) *	1999-05-06	2000-11-09	Bayer Ag	Substituierte Benzoylisoxazole
DE19921424A1 (de) *	1999-05-08	2000-11-09	Bayer Ag	Substituierte Benzoylketone
DE19929348A1 (de)	1999-06-26	2000-12-28	Bayer Ag	Verfahren zur Herstellung von 2-Heterocyclylmethyl-benzoesäurederivaten
US6531142B1 (en) *	1999-08-18	2003-03-11	The Procter & Gamble Company	Stable, electrostatically sprayable topical compositions
DE19943636A1 (de)	1999-09-13	2001-03-15	Bayer Ag	Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943635A1 (de)	1999-09-13	2001-03-15	Bayer Ag	Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943639A1 (de)	1999-09-13	2001-03-15	Bayer Ag	Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
DE19943634A1 (de)	1999-09-13	2001-04-12	Bayer Ag	Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
WO2002066447A1 (en)	2001-02-21	2002-08-29	Ono Pharmaceutical Co., Ltd.	4h-1,2,4-triazole-3(2h)-thione deratives as sphingomyelinase inhibitors
DE10110749A1 (de)	2001-03-07	2002-09-12	Bayer Ag	Substituierte Aminodicarbonsäurederivate
DE10110750A1 (de)	2001-03-07	2002-09-12	Bayer Ag	Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
US20040071757A1 (en) *	2001-11-20	2004-04-15	David Rolf	Inhalation antiviral patch
ATE556060T1 (de) *	2003-03-14	2012-05-15	Merck Sharp & Dohme	Monocyclische anilidspirohydantoine als cgrp- rezeptorantagonisten
US7855190B2 (en)	2003-07-16	2010-12-21	Teva Women's Health, Inc.	Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration
KR20060066141A (ko)	2003-06-27	2006-06-15	버글린 코퍼레이션 오브 워싱턴	사과 및 연한 코아를 가지거나 피트를 가진 다른 과일들을작은 응력을 가지고 정확하게 코아제거하고슬라이스절단하기 위한 기계
WO2005097112A2 (en)	2004-03-08	2005-10-20	Wyeth	Ion channel modulators
BRPI0508510A (pt)	2004-03-08	2007-07-31	Wyeth Corp	moduladores de canal de ìon
BRPI0508532A (pt)	2004-03-08	2007-08-07	Wyeth Corp	moduladores do canal de ìon
BRPI0510340A (pt)	2004-04-28	2007-10-30	Pfizer	derivados de 3-heterociclil-4-feniltriazol como inibidores do receptor via da vasopressina
JP2008524246A (ja)	2004-12-16	2008-07-10	タケダサンディエゴインコーポレイテッド	ヒストンデアセチラーゼ阻害剤
WO2006117657A1 (en)	2005-05-03	2006-11-09	Ranbaxy Laboratories Limited	Triazolone derivatives as anti-inflammatory agents
DE102006024024A1 (de) *	2006-05-23	2007-11-29	Bayer Healthcare Aktiengesellschaft	Substituierte Arylimidazolone und -triazolone sowie ihre Verwendung
WO2008052031A2 (en) *	2006-10-24	2008-05-02	Alcon Research, Ltd.	2-pyrrolidone derivatives for preservation of ophthalmic, otic and nasal compositions
DE102010001064A1 (de) *	2009-03-18	2010-09-23	Bayer Schering Pharma Aktiengesellschaft	Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung

2006
- 2006-05-23 DE DE102006024024A patent/DE102006024024A1/de not_active Withdrawn
2007
- 2007-05-21 DK DK07725514.9T patent/DK2027096T3/da active
- 2007-05-21 RU RU2008150598/04A patent/RU2460724C2/ru not_active IP Right Cessation
- 2007-05-21 AU AU2007253572A patent/AU2007253572B9/en not_active Ceased
- 2007-05-21 PL PL07725514T patent/PL2027096T3/pl unknown
- 2007-05-21 US US12/301,616 patent/US8084481B2/en not_active Expired - Fee Related
- 2007-05-21 BR BRPI0711975-5A patent/BRPI0711975A2/pt not_active IP Right Cessation
- 2007-05-21 JP JP2009511411A patent/JP5247684B2/ja not_active Expired - Fee Related
- 2007-05-21 MX MX2008014797A patent/MX2008014797A/es active IP Right Grant
- 2007-05-21 KR KR1020087031086A patent/KR101426574B1/ko not_active Expired - Fee Related
- 2007-05-21 WO PCT/EP2007/004615 patent/WO2007134862A1/de active Application Filing
- 2007-05-21 CN CN200780027634.4A patent/CN101495458B/zh not_active Expired - Fee Related
- 2007-05-21 CA CA2652834A patent/CA2652834C/en not_active Expired - Fee Related
- 2007-05-21 EP EP07725514A patent/EP2027096B8/de not_active Not-in-force
- 2007-05-22 PE PE2007000627A patent/PE20080706A1/es not_active Application Discontinuation
- 2007-05-22 TW TW096118061A patent/TW200817336A/zh unknown
- 2007-05-23 ES ES07725514T patent/ES2385606T3/es active Active
- 2007-05-23 DO DO2007000102A patent/DOP2007000102A/es unknown
- 2007-05-23 AR ARP070102236A patent/AR061114A1/es not_active Application Discontinuation
- 2007-05-23 PT PT07725514T patent/PT2027096E/pt unknown
- 2007-05-24 UY UY30364A patent/UY30364A1/es not_active Application Discontinuation
2008
- 2008-11-06 IL IL195142A patent/IL195142A/en not_active IP Right Cessation
- 2008-11-06 TN TNP2008000443A patent/TNSN08443A1/en unknown
- 2008-11-19 ZA ZA2008/09860A patent/ZA200809860B/en unknown
- 2008-11-20 SV SV2008003098A patent/SV2009003098A/es not_active Application Discontinuation
- 2008-11-20 GT GT200800250A patent/GT200800250A/es unknown
- 2008-11-21 HN HN2008001720A patent/HN2008001720A/es unknown
- 2008-11-21 EC EC2008008904A patent/ECSP088904A/es unknown
- 2008-12-05 MA MA31452A patent/MA30500B1/fr unknown
2010
- 2010-01-18 HK HK10100511.8A patent/HK1136820A1/xx not_active IP Right Cessation
2011
- 2011-12-26 US US13/337,216 patent/US20130005704A1/en not_active Abandoned

Also Published As

Publication number	Publication date
TW200817336A (en)	2008-04-16
US8084481B2 (en)	2011-12-27
CA2652834A1 (en)	2007-11-29
DOP2007000102A (es)	2007-12-31
SV2009003098A (es)	2009-04-28
CN101495458A (zh)	2009-07-29
AR061114A1 (es)	2008-08-06
AU2007253572B2 (en)	2013-06-20
EP2027096A1 (de)	2009-02-25
JP5247684B2 (ja)	2013-07-24
MX2008014797A (es)	2008-12-02
BRPI0711975A2 (pt)	2012-02-22
CN101495458B (zh)	2014-01-29
ES2385606T3 (es)	2012-07-27
PL2027096T3 (pl)	2012-10-31
DK2027096T3 (da)	2012-09-10
TNSN08443A1 (en)	2010-04-14
KR20090014214A (ko)	2009-02-06
PT2027096E (pt)	2012-07-12
DE102006024024A1 (de)	2007-11-29
RU2008150598A (ru)	2010-06-27
ES2385606T8 (es)	2013-05-14
WO2007134862A1 (de)	2007-11-29
KR101426574B1 (ko)	2014-08-06
EP2027096B8 (de)	2012-09-26
ZA200809860B (en)	2010-02-24
AU2007253572B9 (en)	2013-07-25
CA2652834C (en)	2015-01-27
MA30500B1 (fr)	2009-06-01
PE20080706A1 (es)	2008-08-07
US20130005704A1 (en)	2013-01-03
ECSP088904A (es)	2008-12-30
HN2008001720A (es)	2009-06-10
UY30364A1 (es)	2008-01-02
JP2009537581A (ja)	2009-10-29
GT200800250A (es)	2009-09-14
IL195142A0 (en)	2009-09-22
IL195142A (en)	2013-07-31
US20090312381A1 (en)	2009-12-17
RU2460724C2 (ru)	2012-09-10
EP2027096B1 (de)	2012-05-23
AU2007253572A1 (en)	2007-11-29

Publication	Publication Date	Title
ZA200809860B (en)	2010-02-24	Substituted arylimidazolone and triazolone as inhibitors of vasopressin receptors
GB0622084D0 (en)	2006-12-13	Inhibitors of HSP90
EP2026843A4 (en)	2011-06-22	THERAPEUTIC USES OF RTP801L INHIBITORS
TWI372623B (en)	2012-09-21	Inhibitors of 11β-hydroxysteroid dehydrogenase
ZA200802585B (en)	2009-02-25	Pyridopyrimidinone inhibitors of Pl3Kα
IL190292A0 (en)	2009-09-22	PYRIDOPYRIMIDINONE INHIBITORS OF P13Ka
IL195031A0 (en)	2009-08-03	Uses of dpp-iv inhibitors
IL193587A0 (en)	2009-08-03	Heterobicyclic pyrazole compounds and methods of use
ZA200906946B (en)	2011-05-25	Inhibitors of iap
IL197869A0 (en)	2009-12-24	Compositions of chk1 inhibitors
SI2040728T1 (sl)	2015-12-31	FKBP-L in njegova uporaba za zaviranje angiogeneze
ZA200706345B (en)	2009-08-26	Amino-pyridines as inhibitors of ß-secretase
IL193482A0 (en)	2009-05-04	Hydantoin based kinase inhibitors
EP2084139A4 (en)	2010-12-01	OXAZOLIDINIUM COMPOUNDS AND USE AS HYDRATINE HIBITORS
HK1137756A1 (en)	2010-08-06	Substituted dihydropyrazolones and use thereof as hif-prolyl-4 -hydroxylase inhibitors hif--4-
ZA200902940B (en)	2010-05-26	Substituted pyrazole and triazole compounds as KSP inhibitors
IL197966A0 (en)	2011-08-01	Use of modified cyclosporin
IL193981A0 (en)	2009-08-03	Novel heterocyclic nf-kb inhibitors
GB0808286D0 (en)	2008-06-11	Inhibitors of HSP90
GB0622085D0 (en)	2006-12-13	Inhibitors of HSP90
IL198149A0 (en)	2009-12-24	Novel inhibitors of chymase
GB0608822D0 (en)	2006-06-14	Inhibitors of DHFR
ZA200806993B (en)	2009-09-30	Hydantoin based kinase inhibitors
SI2035379T1 (sl)	2010-10-29	Inhibitorji 11-beta-hidroksisteroid dehidrogeneaze 1
GB0621720D0 (en)	2006-12-13	Inhibitors of ikk- serine-threonine protein kinase

Legal Events

Date	Code	Title	Description
2018-12-14	PC	Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)	Effective date: 20180521